Baxter International Inc. provides a portfolio of renal and hospital products. Its Renal segment provides products and services to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers a comprehensive portfolio to meet the needs of patients across the treatment continuum, including technologies and therapies for peritoneal dialysis, in-center hemodialysis (HD), home HD, continuous renal replacement therapy, and additional dialysis services. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. Baxter International Inc. offers its products through direct sales force, independent distributors or sales agents, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has a collaboration agreement with JW Holdings Corporation to co-develop and distribute parenteral nutritional products containing a novel formulation of omega 3 lipids; and agreement with Celerity Pharmaceutical, LLC to develop certain acute care generic injectable premix and oncolytic molecules. The company was founded in 1931 and is headquartered in Deerfield, Illinois.
Baxter tops Street 3Q forecasts DEERFIELD, Ill. (AP) _ Baxter International Inc. (BAX) on Tuesday reported third-quarter net income of $130 million. The Deerfield, Illinois-based company said it had net income of 24 cents per share. Earnings, adjusted for one-time gains and costs, were 56 cents per share. The results beat Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of 44 cents per share. The drug and medical device maker posted revenue of $2.56 billion in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $2.55 billion. For the current quarter ending in December, Baxter expects its per-share earnings to range from 49 cents to 52 cents. Baxter shares have increased 27 percent since the beginning of the year, while the Standard & Poor's 500 index has increased slightly more than 5 percent.
Analyst Upgrade/Downgrade Update Brokerage firm: RBC Capital Mkts Change: Coverage Reiterated/Price Target Changed Previous Rating: N/A Current Rating: Sector Perform Previous Price Target: $50 Current Price Target: $55
Upcoming dividend information: Ex-Div-Date: 11/30/16 Payment Date: 1/3/17 Dividend: $0.13 Current Price: $46.98 Annual Yield: 1.11%
This one's been a steady gainer and looks to be setting up for a breakout above $66.Pretty consistent ascending support dating back to May. Might take a shot on this one in the next few days.
I had these 2 lines drawn in here at the beginning of 2018 (support and resistance forming a wedge) Look where they meet now... Might be a decent spot to take a shot.
I planned to get in on this, and my alert was triggered, but I was not awake at the time it happened and it had already bounced over 1% by the time I'd seen it. Sucks being back on night shift on Monday and Tuesday nights. I'll watch it again tomorrow if I'm up in time, but may have missed my opportunity.
My timimg was off by 1 day as it dipped through my support lines, but back above them today. Next step is re-taking the 50MA and a push into the 70's
Hit my target today, currently up just under 9%. Was busy all day so I was not around to execute the sell order. Got a limit order in now to sell anywhere over $71.90 tomorrow.